Mycobacterium bovis (BCG, Tokyo strain) was purchased from Japan BCG Laboratory (Tokyo, Japan) and maintained in BD BACTEC™ MGIT™ medium supplemented with OADC Enrichment and PANTA antibiotic mixture (Becton Dickinson Co., 245122, Franklin Lakes, NJ) at 37 °C. Mid-log-phase BCG was prepared at concentrations of 1000 CFU/µl for time-lapse microscopy and 10,000 CFU/µl for drug susceptibility testing in MGIT media by using a bacterium counting chamber (A161, SANSYO, Tokyo, Japan). RFP, INH, PZA, SM, EB, LVFX, TH, and CS were obtained from FUJIFILM Wako (Tokyo, Japan). KM and EVM were obtained from Nacalai Tesque (Tokyo, Japan) and Asahi-Kasei Pharma (Tokyo, Japan), respectively. DLM and BDQ were obtained from Selleck (Houston, TX). These chemicals were dissolved in deionized water (INH, PZA, SM, EB, TH, KM, EVM, and CS), methanol (RFP, TH), 0.1 N hydrochloride (LVFX), or dimethyl sulfoxide (DLM, BDQ), and then sterilized using 0.22-µm MILLEX-GV syringe filters (Millipore, Burlington, MA) prior to being added to MGIT media under aseptic conditions. Perfluorocarbon (Fluorinert™, FC-3283) was obtained from 3M (Maplewood, MN). Live/Dead™ BacLight™ bacterial viability reagent was purchased from Thermo Fisher Scientific (L13152, Waltham, MA). Detailed information on the antibacterial agents used in this study is shown in Supplementary Table 1.
Free full text: Click here